|
|
|
 |
|
 |
Aerosolized AAT **
(Alpha-1 Antitrypsin) Collaboration partners
PARI, a Germany based world leader specializing in inhalation solutions
Indication
 |
Alpha-1 Antitrypsin Deficiency (AATD) |
Characteristics
Ready to use liquid for inhaled administration, 2% solution
Status
|
EMEA (European Medicines Agency) has approved the company's clinical program for Phases II-III clinical trials |
Profile
The benefits of Kamada's high purity AAT for inhalation include:
|
Greater patient convenience |
|
Greater patient compliance |
|
Reduced treatment costs |
|
Larger treatment population |
|
Additional / new potential indications
A survey by the US Alpha-1 Foundation revealed that once AAT therapy by inhalation is available, most of the Alpa-1 Antitrypsin patients would transfer to this therapy |
Kamada's Aerosolized AAT to treat AATD was designated as an Orphan Drug by the FDA and EMEA
** Under development
|
|
|
|
|
More
|
